The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Akero Therapeutics, Inc. COM 00973Y108 168,435 5,830,203 SH   DFND   0 5,830,203 0
Chinook Therapeutics, Inc. COM 16961L106 63,859 4,028,937 SH   DFND   0 4,028,937 0
Stoke Therapeutics, Inc. COM 86150R107 1,062,825 17,161,713 SH   DFND   0 17,161,713 0